In-depth analysis of individual CTCs from patients with CRC revealed the striking heterogeneity of KRAS status within and between patients [53,54], and the occurrence and concordance of these mutations in metastatic CRC may vary between primary tumors, CTCs, and metastatic tumors [54,55,56]. The gene discussed is KRAS; the disease is colorectal carcinoma.